Cases of chilblains have been reported with an unusual frequency in France in the context of the COronaVirus Infectious Disease 2019 (COVID-19) epidemic. Some of these cases have been linked to a virological status in favour of a recent Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) infection. Chilblains are acral inflammatory lesion typically reactive to cold (primary form). There are secondary forms acquired during autoimmune connectivitis such as lupus chilblain or hereditary forms related to type I Interferonopathy. An interferon type I signature has been described in these secondary forms of frostbite but also during the cytokine storm of severe forms of CoV-2 SARS infection. If cases of frostbite are indeed secondary to an SARS-CoV-2 infection, comparative analysis of their immunopathological profiles could provide a better understanding of the inflammatory mechanisms during COVID-19.
Diagnostic Test: Biological Sample Collection
Diagnostic test : biological sample collection at Day 0
Two skin biopsies on chilblain at Day 0 (one biopsy for histological analysis, one biopsy for basic research)
Anal swabbing at Day 0
Blood test at Day 0
Blood test at Month 1
Blood test at Month 2
Inclusion Criteria:
- Patient over the age of majority or a minor over 12 years of age accompanied by
his/her legal representative
- Benefiting from a Social Security scheme
- Informed consent signed by the patient (if major) or by his legal representative (if
minor) after clear, fair and appropriate information about the study.
- Red and swollen lesions of the hands and/or feet evolving for more than 24 hours in
the context of a COVID-19 epidemic.
- PCR SARS-CoV-2 PCR on nasopharyngeal swab with results available, prior to the
inclusion visit.
- Absence of fever or respiratory signs suggestive of COVID-19 for at least 14 days
Exclusion Criteria:
- A person who does not benefit from a Social Security scheme or who does not benefit
from it through a third party.
- Patient who is subject to a judicial safeguard measure
- Allergy to local anaesthetic products
- Fever or respiratory signs suggestive of COVID-19 within 14 days
CHU de Poitiers
Poitiers, France